{
"info": {
"nct_id": "NCT00820872",
"official_title": "Phase II Safety Study of Docetaxel and Carboplatin in Combination With Trastuzumab and Lapatinib in Early Breast Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary invasive adenocarcinoma of the breast fulfilling the following criteria:\n\n * Nonmetastatic disease\n * Operable and adequately excised\n\n * Patients with nonresectable deep margin invasion are eligible provided they have had or will receive radiotherapy to the region\n * Patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumor bed\n * Node-positive OR -negative and determined eligible to receive adjuvant trastuzumab (Herceptin®)\n* No positive or suspicious internal mammary nodes by SNS that have not been or will not be irradiated\n* No supraclavicular lymph node involvement (confirmed by fine needle aspiration or biopsy)\n* Over expression and/or amplification of HER2 in the invasive component of the primary tumor, according to one of the following:\n\n * 3+ over-expression by IHC (> 30% of invasive tumor cells)\n * 2+ or 3+ (in 30% or less neoplastic cells) over-expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification\n * HER2 gene amplification by FISH/CISH (> 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > 2.2.)\n\n * Negative or equivocal overall result (FISH test ratio of < 2.2, < 6.0 HER2-gene copies per nucleus) and staining scores of 0, 1+, 2+, or 3+ (in 30% or less neoplastic cells) by IHC not allowed\n* Hormone receptor status known (estrogen receptor with or without progesterone receptor)\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Hemoglobin ≥ 10.0 g/dL\n* ANC ≥ 1,500/mm^3\n* Platelet count ≥ 100,000/mm^3\n* Serum creatinine ≤ 2.0 times upper limit of normal (ULN)\n* AST and ALT ≤ 2.5 times ULN\n* Alkaline phosphatase ≤ 2.5 times ULN\n* Bilirubin ≤ 1.5 times ULN (≤ 2.0 times ULN if known Gilbert syndrome)\n* Baseline LVEF ≥ 50% measured by ECHO or MUGA scan\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No serious cardiac illness or medical condition including, but not limited to, any of the following:\n\n * History of documented congestive heart failure (any NYHA class) or systolic dysfunction (LVEF < 50%)\n * High-risk uncontrolled arrhythmias (e.g., ventricular tachycardia, high-grade atrioventricular-block [second degree or higher], or supraventricular arrhythmias that are not adequately rate-controlled)\n * Angina pectoris requiring antianginal medication\n * Clinically significant valvular heart disease\n * Evidence of transmural infarction on ECG\n * Poorly controlled hypertension (any reading of systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg)\n* No other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions or illness\n* None of the following:\n\n * Ulcerative colitis\n * Malabsorption syndrome\n * Any disease significantly affecting gastrointestinal function\n * Inability to swallow oral medication\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior mediastinal irradiation except internal mammary-node irradiation for the present breast cancer\n* No prior anti-HER2 therapy for any reason\n* No prior biologic or immunotherapy for breast cancer\n* No prior resection of the stomach or small bowel\n* No other concurrent anticancer therapy including chemotherapeutic agents, biologic agents, or radiotherapy\n* No concurrent anticancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the study chair\n* No concurrent CYP3A4 inhibitors or inducers\n* No concurrent epoetin alfa, including darbepoetin alfa\n* No concurrent oprelvekin"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Histologically confirmed primary invasive adenocarcinoma of the breast fulfilling the following criteria:",
"criterions": [
{
"exact_snippets": "Histologically confirmed primary invasive adenocarcinoma of the breast",
"criterion": "adenocarcinoma of the breast",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically"
},
{
"requirement_type": "invasiveness",
"expected_value": "invasive"
},
{
"requirement_type": "primary",
"expected_value": true
}
]
}
]
},
{
"line": "* Nonmetastatic disease",
"criterions": [
{
"exact_snippets": "Nonmetastatic disease",
"criterion": "metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Operable and adequately excised",
"criterions": [
{
"exact_snippets": "Operable",
"criterion": "operability",
"requirements": [
{
"requirement_type": "status",
"expected_value": "operable"
}
]
},
{
"exact_snippets": "adequately excised",
"criterion": "excision adequacy",
"requirements": [
{
"requirement_type": "status",
"expected_value": "adequately excised"
}
]
}
]
},
{
"line": "* Patients with nonresectable deep margin invasion are eligible provided they have had or will receive radiotherapy to the region",
"criterions": [
{
"exact_snippets": "nonresectable deep margin invasion",
"criterion": "deep margin invasion",
"requirements": [
{
"requirement_type": "resectability",
"expected_value": false
}
]
},
{
"exact_snippets": "provided they have had or will receive radiotherapy to the region",
"criterion": "radiotherapy to the region",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumor bed",
"criterions": [
{
"exact_snippets": "histologically documented infiltration of the skin (pT4)",
"criterion": "skin infiltration",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": "histologically documented"
},
{
"requirement_type": "stage",
"expected_value": "pT4"
}
]
},
{
"exact_snippets": "undergone or will receive radiotherapy encompassing the tumor bed",
"criterion": "radiotherapy",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "radiotherapy encompassing the tumor bed"
}
]
}
]
},
{
"line": "* Node-positive OR -negative and determined eligible to receive adjuvant trastuzumab (Herceptin®)",
"criterions": [
{
"exact_snippets": "Node-positive OR -negative",
"criterion": "node status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"positive",
"negative"
]
}
]
},
{
"exact_snippets": "determined eligible to receive adjuvant trastuzumab (Herceptin®)",
"criterion": "eligibility for adjuvant trastuzumab",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": true
}
]
}
]
},
{
"line": "* No positive or suspicious internal mammary nodes by SNS that have not been or will not be irradiated",
"criterions": [
{
"exact_snippets": "No positive or suspicious internal mammary nodes",
"criterion": "internal mammary nodes",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"not positive",
"not suspicious"
]
}
]
},
{
"exact_snippets": "that have not been or will not be irradiated",
"criterion": "irradiation of internal mammary nodes",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
},
{
"line": "* No supraclavicular lymph node involvement (confirmed by fine needle aspiration or biopsy)",
"criterions": [
{
"exact_snippets": "No supraclavicular lymph node involvement",
"criterion": "supraclavicular lymph node involvement",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "confirmed by fine needle aspiration or biopsy",
"criterion": "confirmation method for lymph node involvement",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"fine needle aspiration",
"biopsy"
]
}
]
}
]
},
{
"line": "* Over expression and/or amplification of HER2 in the invasive component of the primary tumor, according to one of the following:",
"criterions": [
{
"exact_snippets": "Over expression ... of HER2",
"criterion": "HER2",
"requirements": [
{
"requirement_type": "expression",
"expected_value": "over"
}
]
},
{
"exact_snippets": "amplification of HER2",
"criterion": "HER2",
"requirements": [
{
"requirement_type": "amplification",
"expected_value": true
}
]
},
{
"exact_snippets": "invasive component of the primary tumor",
"criterion": "invasive component of the primary tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* 3+ over-expression by IHC (> 30% of invasive tumor cells)",
"criterions": [
{
"exact_snippets": "3+ over-expression by IHC (> 30% of invasive tumor cells)",
"criterion": "3+ over-expression by IHC",
"requirements": [
{
"requirement_type": "percentage of invasive tumor cells",
"expected_value": {
"operator": ">",
"value": 30,
"unit": "%"
}
}
]
}
]
},
{
"line": "* 2+ or 3+ (in 30% or less neoplastic cells) over-expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification",
"criterions": [
{
"exact_snippets": "2+ or 3+ (in 30% or less neoplastic cells) over-expression by IHC",
"criterion": "HER2 over-expression",
"requirements": [
{
"requirement_type": "expression level",
"expected_value": [
"2+",
"3+"
]
},
{
"requirement_type": "cell percentage",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "%"
}
},
{
"requirement_type": "method",
"expected_value": "IHC"
}
]
},
{
"exact_snippets": "in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification",
"criterion": "HER2 gene amplification",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"FISH",
"CISH"
]
},
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* HER2 gene amplification by FISH/CISH (> 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > 2.2.)",
"criterions": [
{
"exact_snippets": "HER2 gene amplification by FISH/CISH (> 6 HER2 gene copies per nucleus",
"criterion": "HER2 gene amplification",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"FISH",
"CISH"
]
},
{
"requirement_type": "gene copies per nucleus",
"expected_value": {
"operator": ">",
"value": 6,
"unit": "HER2 gene copies"
}
}
]
},
{
"exact_snippets": "FISH ratio [HER2 gene copies to chromosome 17 signals] of > 2.2.",
"criterion": "FISH ratio",
"requirements": [
{
"requirement_type": "ratio",
"expected_value": {
"operator": ">",
"value": 2.2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Negative or equivocal overall result (FISH test ratio of < 2.2, < 6.0 HER2-gene copies per nucleus) and staining scores of 0, 1+, 2+, or 3+ (in 30% or less neoplastic cells) by IHC not allowed",
"criterions": [
{
"exact_snippets": "Negative or equivocal overall result (FISH test ratio of < 2.2, < 6.0 HER2-gene copies per nucleus)",
"criterion": "FISH test result",
"requirements": [
{
"requirement_type": "overall result",
"expected_value": {
"operator": "!=",
"value": 0,
"unit": "N/A"
}
},
{
"requirement_type": "FISH test ratio",
"expected_value": {
"operator": "<",
"value": 2.2,
"unit": "N/A"
}
},
{
"requirement_type": "HER2-gene copies per nucleus",
"expected_value": {
"operator": "<",
"value": 6.0,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "staining scores of 0, 1+, 2+, or 3+ (in 30% or less neoplastic cells) by IHC not allowed",
"criterion": "IHC staining score",
"requirements": [
{
"requirement_type": "staining score",
"expected_value": [
"0",
"1+",
"2+",
"3+"
]
},
{
"requirement_type": "neoplastic cells percentage",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Hormone receptor status known (estrogen receptor with or without progesterone receptor)",
"criterions": [
{
"exact_snippets": "Hormone receptor status known (estrogen receptor with or without progesterone receptor)",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "knowledge",
"expected_value": true
}
]
}
]
},
{
"line": "* Menopausal status not specified",
"criterions": [
{
"exact_snippets": "Menopausal status",
"criterion": "menopausal status",
"requirements": [
{
"requirement_type": "specification",
"expected_value": false
}
]
}
]
},
{
"line": "* ECOG performance status 0-1",
"criterions": [
{
"exact_snippets": "ECOG performance status 0-1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Hemoglobin ≥ 10.0 g/dL",
"criterions": [
{
"exact_snippets": "Hemoglobin ≥ 10.0 g/dL",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 10.0,
"unit": "g/dL"
}
}
]
}
]
},
{
"line": "* ANC ≥ 1,500/mm^3",
"criterions": [
{
"exact_snippets": "ANC ≥ 1,500/mm^3",
"criterion": "ANC",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Platelet count ≥ 100,000/mm^3",
"criterions": [
{
"exact_snippets": "Platelet count ≥ 100,000/mm^3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Serum creatinine ≤ 2.0 times upper limit of normal (ULN)",
"criterions": [
{
"exact_snippets": "Serum creatinine ≤ 2.0 times upper limit of normal (ULN)",
"criterion": "serum creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.0,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* AST and ALT ≤ 2.5 times ULN",
"criterions": [
{
"exact_snippets": "AST and ALT ≤ 2.5 times ULN",
"criterion": "AST",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "AST and ALT ≤ 2.5 times ULN",
"criterion": "ALT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* Alkaline phosphatase ≤ 2.5 times ULN",
"criterions": [
{
"exact_snippets": "Alkaline phosphatase ≤ 2.5 times ULN",
"criterion": "alkaline phosphatase",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* Bilirubin ≤ 1.5 times ULN (≤ 2.0 times ULN if known Gilbert syndrome)",
"criterions": [
{
"exact_snippets": "Bilirubin ≤ 1.5 times ULN",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Bilirubin ... ≤ 2.0 times ULN if known Gilbert syndrome",
"criterion": "bilirubin level with Gilbert syndrome",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.0,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* Baseline LVEF ≥ 50% measured by ECHO or MUGA scan",
"criterions": [
{
"exact_snippets": "Baseline LVEF ≥ 50%",
"criterion": "LVEF",
"requirements": [
{
"requirement_type": "baseline measurement",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
}
]
},
{
"exact_snippets": "measured by ECHO or MUGA scan",
"criterion": "measurement method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"ECHO",
"MUGA scan"
]
}
]
}
]
},
{
"line": "* Negative pregnancy test",
"criterions": [
{
"exact_snippets": "Negative pregnancy test",
"criterion": "pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
}
]
}
]
},
{
"line": "* Fertile patients must use effective contraception",
"criterions": [
{
"exact_snippets": "Fertile patients",
"criterion": "fertility",
"requirements": [
{
"requirement_type": "status",
"expected_value": "fertile"
}
]
},
{
"exact_snippets": "must use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
},
{
"line": "* No serious cardiac illness or medical condition including, but not limited to, any of the following:",
"criterions": [
{
"exact_snippets": "serious cardiac illness",
"criterion": "cardiac illness",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "not serious"
}
]
},
{
"exact_snippets": "medical condition",
"criterion": "medical condition",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "not serious"
}
]
}
]
},
{
"line": "* History of documented congestive heart failure (any NYHA class) or systolic dysfunction (LVEF < 50%)",
"criterions": [
{
"exact_snippets": "History of documented congestive heart failure (any NYHA class)",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "systolic dysfunction (LVEF < 50%)",
"criterion": "systolic dysfunction",
"requirements": [
{
"requirement_type": "LVEF",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "%"
}
}
]
}
]
},
{
"line": "* High-risk uncontrolled arrhythmias (e.g., ventricular tachycardia, high-grade atrioventricular-block [second degree or higher], or supraventricular arrhythmias that are not adequately rate-controlled)",
"criterions": [
{
"exact_snippets": "High-risk uncontrolled arrhythmias",
"criterion": "arrhythmias",
"requirements": [
{
"requirement_type": "risk level",
"expected_value": "high-risk"
},
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "ventricular tachycardia",
"criterion": "ventricular tachycardia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "high-grade atrioventricular-block [second degree or higher]",
"criterion": "atrioventricular-block",
"requirements": [
{
"requirement_type": "grade",
"expected_value": ">= second degree"
}
]
},
{
"exact_snippets": "supraventricular arrhythmias that are not adequately rate-controlled",
"criterion": "supraventricular arrhythmias",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "not adequately rate-controlled"
}
]
}
]
},
{
"line": "* Angina pectoris requiring antianginal medication",
"criterions": [
{
"exact_snippets": "Angina pectoris requiring antianginal medication",
"criterion": "angina pectoris",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "antianginal medication"
}
]
}
]
},
{
"line": "* Clinically significant valvular heart disease",
"criterions": [
{
"exact_snippets": "Clinically significant valvular heart disease",
"criterion": "valvular heart disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "clinically significant"
}
]
}
]
},
{
"line": "* Evidence of transmural infarction on ECG",
"criterions": [
{
"exact_snippets": "Evidence of transmural infarction on ECG",
"criterion": "transmural infarction",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": true
}
]
}
]
},
{
"line": "* Poorly controlled hypertension (any reading of systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg)",
"criterions": [
{
"exact_snippets": "Poorly controlled hypertension",
"criterion": "hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": "poorly controlled"
}
]
},
{
"exact_snippets": "systolic BP > 180 mm Hg",
"criterion": "systolic blood pressure",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 180,
"unit": "mm Hg"
}
}
]
},
{
"exact_snippets": "diastolic BP > 100 mm Hg",
"criterion": "diastolic blood pressure",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 100,
"unit": "mm Hg"
}
}
]
}
]
},
{
"line": "* No other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions or illness",
"criterions": [
{
"exact_snippets": "No other concurrent serious diseases",
"criterion": "concurrent serious diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "severe pulmonary conditions",
"criterion": "severe pulmonary conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "illness",
"criterion": "illness",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Ulcerative colitis",
"criterions": [
{
"exact_snippets": "Ulcerative colitis",
"criterion": "ulcerative colitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Malabsorption syndrome",
"criterions": [
{
"exact_snippets": "Malabsorption syndrome",
"criterion": "malabsorption syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Any disease significantly affecting gastrointestinal function",
"criterions": [
{
"exact_snippets": "disease significantly affecting gastrointestinal function",
"criterion": "gastrointestinal function",
"requirements": [
{
"requirement_type": "impact",
"expected_value": "significant"
}
]
}
]
},
{
"line": "* Inability to swallow oral medication",
"criterions": [
{
"exact_snippets": "Inability to swallow oral medication",
"criterion": "ability to swallow oral medication",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY:",
"criterions": [
{
"exact_snippets": "PRIOR CONCURRENT THERAPY",
"criterion": "prior concurrent therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* See Disease Characteristics",
"criterions": [
{
"exact_snippets": "Disease Characteristics",
"criterion": "disease characteristics",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "See Disease Characteristics"
}
]
}
]
},
{
"line": "* No prior mediastinal irradiation except internal mammary-node irradiation for the present breast cancer",
"criterions": [
{
"exact_snippets": "No prior mediastinal irradiation",
"criterion": "prior mediastinal irradiation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "internal mammary-node irradiation for the present breast cancer",
"criterion": "internal mammary-node irradiation",
"requirements": [
{
"requirement_type": "purpose",
"expected_value": "present breast cancer"
}
]
}
]
},
{
"line": "* No prior anti-HER2 therapy for any reason",
"criterions": [
{
"exact_snippets": "No prior anti-HER2 therapy",
"criterion": "anti-HER2 therapy",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": false
}
]
}
]
},
{
"line": "* No prior biologic or immunotherapy for breast cancer",
"criterions": [
{
"exact_snippets": "No prior biologic ... for breast cancer",
"criterion": "biologic therapy for breast cancer",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": false
}
]
},
{
"exact_snippets": "No prior ... immunotherapy for breast cancer",
"criterion": "immunotherapy for breast cancer",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": false
}
]
}
]
},
{
"line": "* No prior resection of the stomach or small bowel",
"criterions": [
{
"exact_snippets": "No prior resection of the stomach",
"criterion": "stomach resection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No prior resection of the ... small bowel",
"criterion": "small bowel resection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No other concurrent anticancer therapy including chemotherapeutic agents, biologic agents, or radiotherapy",
"criterions": [
{
"exact_snippets": "No other concurrent anticancer therapy including chemotherapeutic agents",
"criterion": "concurrent anticancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other concurrent anticancer therapy including ... biologic agents",
"criterion": "concurrent biologic agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other concurrent anticancer therapy including ... radiotherapy",
"criterion": "concurrent radiotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No concurrent anticancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the study chair",
"criterions": [
{
"exact_snippets": "No concurrent anticancer treatment in another investigational trial",
"criterion": "concurrent anticancer treatment in another investigational trial",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "hormone therapy",
"criterion": "hormone therapy",
"requirements": [
{
"requirement_type": "concurrent treatment",
"expected_value": false
}
]
},
{
"exact_snippets": "immunotherapy",
"criterion": "immunotherapy",
"requirements": [
{
"requirement_type": "concurrent treatment",
"expected_value": false
}
]
}
]
},
{
"line": "* No concurrent epoetin alfa, including darbepoetin alfa",
"criterions": [
{
"exact_snippets": "No concurrent epoetin alfa",
"criterion": "epoetin alfa",
"requirements": [
{
"requirement_type": "concurrent use",
"expected_value": false
}
]
},
{
"exact_snippets": "including darbepoetin alfa",
"criterion": "darbepoetin alfa",
"requirements": [
{
"requirement_type": "concurrent use",
"expected_value": false
}
]
}
]
},
{
"line": "* No concurrent oprelvekin",
"criterions": [
{
"exact_snippets": "No concurrent oprelvekin",
"criterion": "oprelvekin",
"requirements": [
{
"requirement_type": "concurrent use",
"expected_value": false
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "DISEASE CHARACTERISTICS:",
"criterions": []
},
{
"line": "PATIENT CHARACTERISTICS:",
"criterions": []
},
{
"line": "* Not pregnant or nursing",
"criterions": [
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "not ... nursing",
"criterion": "nursing status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
},
{
"line": "* None of the following:",
"criterions": []
},
{
"line": "* No concurrent CYP3A4 inhibitors or inducers",
"criterions": [
{
"exact_snippets": "No concurrent CYP3A4 inhibitors",
"criterion": "CYP3A4 inhibitors",
"requirements": [
{
"requirement_type": "concurrent use",
"expected_value": false
}
]
},
{
"exact_snippets": "No concurrent ... CYP3A4 inducers",
"criterion": "CYP3A4 inducers",
"requirements": [
{
"requirement_type": "concurrent use",
"expected_value": false
}
]
}
]
}
]
}